Inhibition of Preretinal and Optic Nerve Head Neovascularization in Pigs by Intravitreal Triamcinolone Acetonide

Danis, Ronald P.; Bingaman, David P.; Yang, Yishuang; Ladd, Byron

doi:10.1016/s0161-6420(96)30383-7

Cited by 142 publications

(95 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 These clinical studies are in agreement with experimental studies on an angiostatic effect of intravitreal cortisone on experimental subretinal neovascularization and other types of intraocular blood vessel proliferation. 4,5,7,29 The results of the present study show less beneficial results than the previous studies mentioned above. Although visual acuity improved significantly from baseline to a mean maximum during follow-up defined as the best measurement of all postinjection measurements, the comparison between the baseline value and the measurements at specific postinjection examination dates showed that during the first 3 months after the injection, visual acuity stabilized, and that at 6 months and later after the injection, visual acuity started to deteriorate significantly ( Table 1).…”

Section: Discussioncontrasting

confidence: 93%

Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration

Jonas

Spandau

Kamppeter

et al. 2006

Eye

View full text Add to dashboard Cite

Purpose To report on the follow-up of patients who received an intravitreal triamcinolone acetonide injection (IVTA) as treatment of exudative age-related macular degeneration.Methods The clinical interventional caseseries study included 205 patients (222 eyes) with progressive exudative age-related macular degeneration with subfoveal neovascularization who consecutively received an IVTA of about 20 mg as only therapeutic procedure and for whom follow-up was at least 3 months. Mean follow-up was 10.477.1 months (range, 3-35.7 months). Results Visual acuity improved significantly (Po0.001) from baseline (0.9070.45 logarithm of the minimum angle of resolution (LogMar)) to a mean minimum of 0.7970.42 LogMar during follow-up. In 86 (38.7%) eyes and in 55 (24.8%) eyes, best visual acuity increased by at least two and three Snellen lines, respectively. Comparing the measurements at specific postinjection examination dates showed that visual acuity measurements taken at 1, 2, and 3 months after injection were not significantly different from the baseline value. Measurements taken at 6, 9, and 12 months after the injection were significantly (Po0.001) lower than the measurements at baseline. Mean loss at 6 months was 1.473.8 Snellen lines, at 9 months, 2.574.6 lines, and at 12 months after the injection, 2.674.0 lines. Intraocular pressure increased significantly (Po0.001) during the first 6 months, and returned to baseline at 9 months after injection.Conclusions Single injection high-dosage IVTA did not show an apparent benefit at 12 months after injection in patients with neovascular age-related macular degeneration.

show abstract

Section: Discussioncontrasting

confidence: 93%

Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration

Jonas

Spandau

Kamppeter

et al. 2006

Eye

View full text Add to dashboard Cite

show abstract

“…It is in agreement with experimental studies on an angiostatic effect of intravitreal cortisone on experimental subretinal neovascularization and other types of intraocular blood vessel proliferation. 34,[35][36][37]39 An additional reason for the discrepancy between the study by Gillies and colleagues and the present as well as the preceding studies may be that Gillies' investigation included patients with the classic type of subfoveal neovascularization, which is associated with a worse prognosis compared to the occult type of subfoveal neovascularization.…”

Section: Discussioncontrasting

confidence: 62%

“…Consequently, other treatment modalities have been investigated, one of which is the intravitreal application of triamcinolone acetonide with its anti-oedematous and antiangiogenic effect, demonstrated in experimental investigations and clinical studies. [34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] Penfold et al 38 started to inject triamcinolone acetonide intravitreally in an effort to treat exudative age-related macular degeneration medically. 40 In 1998, Challa et al 40 evaluated the safety and efficacy of intravitreal triamcinolone after a follow-up of 18 months in patients with exudative age-related macular degeneration considered unsuitable for laser photocoagulation.…”

Section: Discussionmentioning

confidence: 99%

“…These clinical studies were supported by experimental studies on the effect of intravitreal cortisone on experimental subretinal neovascularization and other types of intraocular proliferation of blood vessel. [34][35][36][37]39,[42][43][44] Another recent investigation including 71 eyes with exudative agerelated macular degeneration demonstrated a significant increase in visual acuity after an intravitreal injection of 25 mg of triamcinolone acetonide. 48 The improvement in visual acuity was significant at 1 month (P ¼ 0.04) and 2 months (P ¼ 0.04) after the injection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study

Jonas

Degenring

Kreissig

et al. 2004

Eye

View full text Add to dashboard Cite

Exudative agerelated macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study JB Jonas, RF Degenring, I Kreissig, T Friedemann and I Akkoyun Abstract Purpose To report on visual outcome of patients receiving an intravitreal injection of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Methods The prospective comparative nonrandomized clinical interventional study included 187 consecutive patients with progressive exudative age-related macular degeneration, divided into a study group of 115 patients receiving an intravitreal injection of 25 mg triamcinolone acetonide, and a control group of 72 patients without treatment. The mean follow-up was 6.074.2 months. Results Visual acuity increased significantly (P ¼ 0.03) in the study group, and decreased significantly (P ¼ 0.01) in the control group, at 1 month and 3 months after start of the study. Between the study group and control group, the differences in change of visual acuity were significant (P ¼ 0.001). In the study group, the number of patients with an increase in visual acuity of 2 or more Snellen lines was significantly (P ¼ 0.001) larger than in the control group. Correspondingly, the number of patients with a decrease of 2 or more Snellen lines was significantly (P ¼ 0.007) smaller in the study group. In all, 43 (37.4%) patients of the study group experienced an increase in best visual acuity by 2 or more Snellen lines.Conclusions Visual acuity increased in patients with exudative age-related macular degeneration at 1 month and 3 months after an intravitreal injection of 25 mg triamcinolone acetonide.

show abstract

“…Changes in PKC activity and isoform-specific increases in PKC in the membrane fraction have also been noted during ischemic neurodegeneration in the cerebellum and hippocampus in a canine model (50,51). Fewer experiments have addressed the role of PKC␤II in ischemia, although a recent study has employed the PKC␤ inhibitor LY333531 in a porcine model of ischemia-induced preretinal neovascularization (52). Administration of the PKC␤ inhibitor suppressed neovascularization, consistent with a contribution of PKC␤ to cellular events underlying angiogenesis.…”

Section: Discussionmentioning

confidence: 90%

Hypoxia-associated Induction of Early Growth Response-1 Gene Expression

Yan¹,

Lu²,

Zou³

et al. 1999

Journal of Biological Chemistry

236

187

View full text Add to dashboard Cite

1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8298 -8303). Now, we show that cultured monocytes subjected to hypoxia (pO 2 Ϸ 12 torr) displayed increased Egr-1 expression because of de novo biosynthesis, with a Ϸ10-fold increased rate of transcription. Transfection of monocytes with Egr-1 promoter-luciferase constructs localized elements responsible for hypoxia-enhanced expression to ؊424/؊65, a region including EBS (ets binding site)-SRE (serum response element)-EBS and SRE-EBS-SRE sites. Further studies with each of these regions ligated to the basal thymidine kinase promoter and luciferase demonstrated that EBS sites in the element spanning ؊424/؊375 were critical for hypoxia-enhanceable gene expression. These data suggested that an activated ets factor, such as Elk-1, in complex with serum response factor, was the likely proximal trigger of Egr-1 transcription. Indeed, hypoxia induced activation of Elk-1, and suppression of Elk-1 blocked up-regulation of Egr-1 transcription. The signaling cascade preceding Elk-1 activation in response to oxygen deprivation was traced to activation of protein kinase C-␤II, Raf, mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase and mitogen-activated protein kinases. Comparable hypoxiamediated Egr-1 induction and activation were observed in cultured hepatoma-derived cells deficient in HIF-1␤ and wild-type hepatoma cells, indicating that the HIF-1 and Egr-1 pathways are initiated independently in response to oxygen deprivation. We propose that activation of Egr-1 in response to hypoxia induces a different facet of the adaptive response than HIF-1, one component of which causes expression of tissue factor, resulting in fibrin deposition.

show abstract

Inhibition of Preretinal and Optic Nerve Head Neovascularization in Pigs by Intravitreal Triamcinolone Acetonide

Cited by 142 publications

References 22 publications

Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration

Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration

Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study

Hypoxia-associated Induction of Early Growth Response-1 Gene Expression

Contact Info

Product

Resources

About